[Direct oral anticoagulants: what is the exact assessment of coagulation tests and plasma levels by laboratory tests in clinical practice?]

Ann Biol Clin (Paris). 2016 Jan-Feb;74(1):69-77. doi: 10.1684/abc.2015.1110.
[Article in French]

Abstract

Direct oral anticoagulants (DAO), anti-IIa or anti-Xa, are intended to be widely used for the treatment and prevention of thrombotic disorders in venous thromboembolic disease and atrial fibrillation as an alternative of vitamin K antagonists (VKA). Despite predictable pharmacological properties, spontaneous or provoked hemorrhagic risks by DAO are major limitations. Thus, after few years of inconsistence concerning biological implication and in particular coagulation tests, it is now established that we need biology to evaluate hemorrhagic risk before surgery or in hemorrhagic cases.

Keywords: apixaban; coagulation test; dabigatran; direct oral anticoagulants; rivaroxaban.

Publication types

  • Review

MeSH terms

  • Administration, Oral
  • Anticoagulants / administration & dosage*
  • Anticoagulants / blood*
  • Anticoagulants / pharmacokinetics
  • Blood Chemical Analysis / methods
  • Blood Chemical Analysis / statistics & numerical data
  • Blood Coagulation / drug effects
  • Blood Coagulation / physiology
  • Blood Coagulation Tests
  • Clinical Laboratory Techniques* / methods
  • Clinical Laboratory Techniques* / statistics & numerical data
  • Humans
  • Monitoring, Physiologic / methods
  • Practice Patterns, Physicians'* / statistics & numerical data
  • Thromboembolism / blood*
  • Thromboembolism / drug therapy*

Substances

  • Anticoagulants